Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer

NCT05736952 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Program changed

Conditions

Platinum-resistant Ovarian Cancer

Interventions

DRUG: Oral Topotecan Combined With Anlotinib

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine